CD8A and neoplasm: To our knowledge, this study is the first to show the presence of CD8+CD11c+ T cells in a tumor-associated-antigen based therapeutic cancer vaccine system, and the data suggest that these cells are in higher numbers, are more robust, and are more potent with the combination treatments compared to vaccine alone or treatments alone.